Delisted from NASDAQ in Nov 2023
FREQ - Frequency Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Lexington,
United States
Type: Equity
FREQ price evolution
FREQ
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $43.69 | $41.67 | $42.55 | $53.65 |
| Short term investments | $6.77 | $25.8 | $31.14 | |
| Net receivables | $0.45 | |||
| Inventory | ||||
| Total current assets | $42.5 | $48.38 | $69.29 | $87.49 |
| Long term investments | ||||
| Property, plant & equipment | $1.88 | $29.04 | $30.18 | $31.72 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.85 | $31 | $32.21 | $33.74 |
| Total investments | $6.77 | $25.8 | $31.14 | |
| Total assets | $46.35 | $79.38 | $101.5 | $121.24 |
| Current liabilities | ||||
| Accounts payable | $0.34 | $1.29 | $2.71 | $3.11 |
| Deferred revenue | ||||
| Short long term debt | $1.43 | $2.16 | $13.76 | $12.02 |
| Total current liabilities | $9.61 | $8.33 | $22.04 | $21.03 |
| Long term debt | $25.65 | $26.21 | $4.17 | |
| Total noncurrent liabilities | $25.65 | $26.21 | $31.02 | |
| Total debt | $1.43 | $27.81 | $39.97 | $42.95 |
| Total liabilities | $9.61 | $33.98 | $48.25 | $52.04 |
| Shareholders' equity | ||||
| Retained earnings | -$303.62 | -$292 | -$281.21 | -$261.67 |
| Other shareholder equity | $0.01 | -$0.01 | -$0.06 | -$0.2 |
| Total shareholder equity | $36.74 | $45.41 | $53.25 | $69.19 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $53.65 | $81.33 | $222.16 | $200.16 |
| Short term investments | $31.14 | $51.07 | $17.2 | |
| Net receivables | $0.45 | $0.14 | $0.3 | $0.8 |
| Inventory | ||||
| Total current assets | $87.49 | $134.75 | $225.06 | $221.35 |
| Long term investments | $11.72 | |||
| Property, plant & equipment | $31.72 | $36.87 | $37.84 | $1.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $33.74 | $50.61 | $39.66 | $1.86 |
| Total investments | $31.14 | $62.79 | $17.2 | |
| Total assets | $121.24 | $185.36 | $264.72 | $223.22 |
| Current liabilities | ||||
| Accounts payable | $3.11 | $2.75 | $5.51 | $1.22 |
| Deferred revenue | $14.07 | $51.05 | ||
| Short long term debt | $12.02 | $2.58 | $0.4 | |
| Total current liabilities | $21.03 | $11.43 | $26.63 | $52.78 |
| Long term debt | $4.17 | $43.02 | $45.6 | |
| Total noncurrent liabilities | $31.02 | $43.1 | $45.6 | $3.08 |
| Total debt | $42.95 | $45.6 | $45.99 | |
| Total liabilities | $52.04 | $54.53 | $72.23 | $55.86 |
| Shareholders' equity | ||||
| Retained earnings | -$261.67 | -$180.09 | -$95.4 | -$68.89 |
| Other shareholder equity | -$0.2 | -$0.06 | $0.03 | $0.05 |
| Total shareholder equity | $69.19 | $130.82 | $192.49 | $167.36 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.56 | $4.59 | $11.36 | $10.65 |
| Selling, general & administrative | $10.11 | $7.24 | $9.16 | $7.55 |
| Total operating expenses | $12.66 | $11.83 | $20.51 | $18.2 |
| Operating income | -$12.66 | -$11.83 | -$20.51 | -$18.2 |
| Income from continuing operations | ||||
| EBIT | -$12.07 | -$11.14 | -$19.76 | -$17.5 |
| Income tax expense | -$0.01 | $0.01 | $0.02 | $0.01 |
| Interest expense | -$0.45 | -$0.35 | -$0.24 | -$0.14 |
| Net income | ||||
| Net income | -$11.61 | -$10.8 | -$19.54 | -$17.36 |
| Income (for common shares) | -$11.61 | -$10.8 | -$19.54 | -$17.36 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14.07 | $36.98 | $28.95 | |
| Cost of revenue | ||||
| Gross Profit | $14.07 | $36.98 | $28.95 | |
| Operating activities | ||||
| Research & development | $49.42 | $60.92 | $37.41 | $18.78 |
| Selling, general & administrative | $33.58 | $37.18 | $27.12 | $14.84 |
| Total operating expenses | $83 | $98.1 | $64.53 | $49.62 |
| Operating income | -$83 | -$84.03 | -$27.55 | -$20.68 |
| Income from continuing operations | ||||
| EBIT | -$81.95 | -$84.3 | -$27.47 | -$20.53 |
| Income tax expense | -$0 | $0.01 | $0.04 | |
| Interest expense | -$0.37 | $0.37 | -$0.99 | -$1.78 |
| Net income | ||||
| Net income | -$81.58 | -$84.69 | -$26.51 | -$18.75 |
| Income (for common shares) | -$81.58 | -$84.69 | -$26.51 | -$19.8 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Net income | -$11.61 | -$10.8 | -$19.54 | -$17.36 |
| Operating activities | ||||
| Depreciation | $1.02 | $1.13 | $1.63 | $1.28 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.92 | $2.9 | $3.43 | $4.41 |
| Total cash flows from operations | -$4.8 | -$8.42 | -$14.13 | -$15.62 |
| Investing activities | ||||
| Capital expenditures | $0.04 | $0.01 | -$0.09 | -$0 |
| Investments | $6.77 | $19.2 | $5.59 | $24.56 |
| Total cash flows from investing | $6.82 | $19.21 | $5.5 | $24.56 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0 | $0.03 | ||
| Net borrowings | -$11.67 | -$2.5 | -$0.83 | |
| Total cash flows from financing | $0 | -$11.67 | -$2.47 | -$0.83 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $2.02 | -$0.88 | -$11.1 | $8.11 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$81.58 | -$84.69 | -$26.51 | -$18.75 |
| Operating activities | ||||
| Depreciation | $5.14 | $3.84 | $1.58 | $0.81 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $19.83 | $21.75 | $9.98 | $3.61 |
| Total cash flows from operations | -$58.24 | -$76.06 | -$45.19 | $34.22 |
| Investing activities | ||||
| Capital expenditures | $0.02 | -$2.91 | -$6.67 | -$1.06 |
| Investments | $31.12 | -$63.21 | $17.07 | -$17.2 |
| Total cash flows from investing | $31.13 | -$66.13 | $10.4 | -$18.26 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.26 | $1.36 | $41.69 | $80.06 |
| Net borrowings | -$0.83 | $15 | ||
| Total cash flows from financing | -$0.58 | $1.36 | $56.69 | $142.01 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$27.68 | -$140.83 | $21.9 | $157.97 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$55.40M |
| EBIT | -$60.46M |
| Net Income | -$59.31M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -68.09% |
| ROE | -115.97% |
| Debt/Equity | 0.75 |
|---|---|
| Net debt/EBITDA | 0.62 |
| Current ratio | 4.42 |
| Quick ratio | 4.42 |